3,5,6,7,8,3',4'-Heptemthoxyflavone

Name: 3,5,6,7,8,3',4'-Heptemthoxyflavone
Brand: MedChemExpress
SKU: HY-N2038
Rating: 4.5 (1 reviews)

Cat. No.: HY-N2038 Purity: 99.85%: FAQs
Data Sheet SDS COA Handling Instructions

Molarity Calculator

3,5,6,7,8,3',4'-Heptemthoxyflavone, a flavonoid from satsuma peel, is an orally available CREB activator with anti-tumor and anti-neuroinflammatory activity. 3,5,6,7,8,3',4'-Heptemthoxyflavone inhibits collagenase activity and increases the content of type I procollagen in human dermal fibroblast neoblast (HDFn) cells. 3,5,6,7,8,3',4'-Heptemthoxyflavone induces brain-derived neurotrophic factor (BDNF) expression through the cAMP/ERK/CREB signaling pathway and reduces phosphodiesterase activity in C6 glioma.

For research use only. We do not sell to patients.

3,5,6,7,8,3',4'-Heptemthoxyflavone Chemical Structure

CAS No. : 1178-24-1

Size	Price	Stock	Quantity
1 mg	USD 110	In-stock	Estimated Time of Arrival: December 31
5 mg	USD 270	In-stock	Estimated Time of Arrival: December 31
10 mg	USD 400	In-stock	Estimated Time of Arrival: December 31
50 mg		Get quote
100 mg		Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Other Forms of 3,5,6,7,8,3',4'-Heptemthoxyflavone:

3,5,6,7,8,3',4'-Heptemthoxyflavone (Standard) Get quote

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All Phosphodiesterase (PDE) Isoform Specific Products:

View All Isoforms

PDE1 PDE2 PDE3 PDE4 PDE5 PDE6 PDE7 PDE9 PDE10 PDE11 PDE12 PDE8 Autotaxin

Biological Activity
Purity & Documentation
References
Customer Review

Description

Cellular Effect

Cell Line	Type	Value	Description	References
A2780 ADR	IC₅₀	9 μM Compound: 21	Inhibition of P-gp expressed in A2780adr cells by calcein AM accumulation assay Inhibition of P-gp expressed in A2780adr cells by calcein AM accumulation assay	[PMID: 21354800]
HL-60	IC₅₀	13.31 μM Compound: III, HeptaMF	Antiproliferative activity against HL60 after 24 hrs Antiproliferative activity against HL60 after 24 hrs	[PMID: 17391969]
HT-29	IC₅₀	30 μM Compound: 3	Anticancer activity against human HT-29 cells after 72 hrs by MTT assay Anticancer activity against human HT-29 cells after 72 hrs by MTT assay	[PMID: 19054677]
MCF7	IC₅₀	1.6 μM Compound: 21	Inhibition of BCRP expressed in MCF-7 MX cells using Hoechst 33342 staining Inhibition of BCRP expressed in MCF-7 MX cells using Hoechst 33342 staining	[PMID: 21354800]
MDCK	IC₅₀	1.4 μM Compound: 21	Inhibition of BCRP expressed in MDCK cells using Hoechst 33342 staining Inhibition of BCRP expressed in MDCK cells using Hoechst 33342 staining	[PMID: 21354800]
MDCK	IC₅₀	31 μM Compound: 21	Inhibition of MDR1 expressed in MDCK cells using rhodamine 123 staining by flow cytometry Inhibition of MDR1 expressed in MDCK cells using rhodamine 123 staining by flow cytometry	[PMID: 21354800]
Monocyte	IC₅₀	12.3 μM Compound: HMF	Inhibition of IL10 expression in LPS-stimulated human monocytes treated 30 mins before LPS challenge measured after 14 hrs by ELISA Inhibition of IL10 expression in LPS-stimulated human monocytes treated 30 mins before LPS challenge measured after 14 hrs by ELISA	[PMID: 10096854]
Monocyte	IC₅₀	5 μM Compound: HMF	Inhibition of TNFalpha expression in LPS-stimulated human monocytes treated 30 mins before LPS challenge measured after 14 hrs by ELISA Inhibition of TNFalpha expression in LPS-stimulated human monocytes treated 30 mins before LPS challenge measured after 14 hrs by ELISA	[PMID: 10096854]
Monocyte	IC₅₀	7.3 μM Compound: HMF	Inhibition of MIP1alpha expression in LPS-stimulated human monocytes treated 30 mins before LPS challenge measured after 14 hrs by ELISA Inhibition of MIP1alpha expression in LPS-stimulated human monocytes treated 30 mins before LPS challenge measured after 14 hrs by ELISA	[PMID: 10096854]

In Vitro

3,5,6,7,8,3',4'-Heptemthoxyflavone (HMF) (50-400 μg/mL; 24 h) does not affect neonatal human dermal fibroblasts at concentrations <200 μg/mL (HDFn) cell viability^[1].
3,5,6,7,8,3',4'-Heptemthoxyflavone (50-200 μg/mL; 24 h) significantly increases type I procollagen content of HDFn cells in a dose-dependent manner. and downregulates the expression of MMP-1, while upregulating the expression of type I procollagen in UV-induced HDFn cells^[1].
3,5,6,7,8,3',4'-Heptemthoxyflavone (HMF) (10 μM; 48 h) can activate ERK and cAMP response element binding protein (CREB), inhibit the activities of PDE4B and PDE4D, and increase cAMP levels in C6 glioma cell^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

3, 5, 6, 7, 8, 3', 4'- Heptemthoxyflavone (HPT) (0.025‰ w/v; po, in water; 2 weeks before tumor induction) inhibits NOR1/TPA-induced tumor promotion in mice^[2].
3, 5, 6, 7, 8, 3', 4'- Heptemthoxyflavone (HMF) (50 mg/kg, 100 mg/kg; po; once daily for 15 days) also exerts neuroprotective effects by enhancing the expression of BDNF in astrocyte in Corticosterone (HY-B1618)-induced depression-like mouse model^[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Molecular Weight

432.42

Formula

C₂₂H₂₄O₉

CAS No.

1178-24-1

Appearance

Solid

Color

White to off-white

SMILES

O=C1C(OC)=C(C2=CC=C(OC)C(OC)=C2)OC3=C(OC)C(OC)=C(OC)C(OC)=C13

Structure Classification

Initial Source

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

4°C, protect from light

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Solvent & Solubility

In Vitro:

DMSO : 50 mg/mL (115.63 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.3126 mL	11.5628 mL	23.1257 mL
5 mM	0.4625 mL	2.3126 mL	4.6251 mL
10 mM	0.2313 mL	1.1563 mL	2.3126 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: 2.5 mg/mL (5.78 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (5.78 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 99.85%

Select Batch:

Data Sheet (279 KB) SDS (251 KB)

COA (253 KB) HNMR (264 KB) CNMR (268 KB) RP-HPLC (291 KB) MS (266 KB)

Handling Instructions (2659 KB)

References

[1]. Kim HI, et al. 3,5,6,7,8,3',4'-Heptamethoxyflavone, a Citrus Flavonoid, Inhibits Collagenase Activity and Induces Type I Procollagen Synthesis in HDFn Cells. Int J Mol Sci. 2018 Feb 22;19(2). [Content Brief]

[2]. Iwase Y, et al. Cancer chemopreventive activity of 3,5,6,7,8,3',4'-heptamethoxyflavone from the peel of citrus plants. Cancer Lett. 2001 Feb 10;163(1):7-9. [Content Brief]

[3]. Adhikari-Devkota A, et al. Anti-neuroinflammatory activities of extract and polymethoxyflavonoids from immature fruit peels of Citrus 'Hebesu'. J Food Biochem. 2019 Jun;43(6):e12813. [Content Brief]

[4]. Sawamoto A, et al. Citrus flavonoid 3,5,6,7,8,3',4'-heptamethoxyflavone induces BDNF via cAMP/ERK/CREB signaling and reduces phosphodiesterase activity in C6 cells. Pharmacol Rep. 2019 Aug;71(4):653-658. [Content Brief]

[5]. Sawamoto A, et al. 3,5,6,7,8,3',4'-Heptamethoxyflavone Ameliorates Depressive-Like Behavior and Hippocampal Neurochemical Changes in Chronic Unpredictable Mild Stressed Mice by Regulating the Brain-Derived Neurotrophic Factor: Requirement for ERK Activation. Int J Mol Sci. 2017 Oct 12;18(10):2133. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	2.3126 mL	11.5628 mL	23.1257 mL	57.8142 mL
	5 mM	0.4625 mL	2.3126 mL	4.6251 mL	11.5628 mL
	10 mM	0.2313 mL	1.1563 mL	2.3126 mL	5.7814 mL
	15 mM	0.1542 mL	0.7709 mL	1.5417 mL	3.8543 mL
	20 mM	0.1156 mL	0.5781 mL	1.1563 mL	2.8907 mL
	25 mM	0.0925 mL	0.4625 mL	0.9250 mL	2.3126 mL
	30 mM	0.0771 mL	0.3854 mL	0.7709 mL	1.9271 mL
	40 mM	0.0578 mL	0.2891 mL	0.5781 mL	1.4454 mL
	50 mM	0.0463 mL	0.2313 mL	0.4625 mL	1.1563 mL
	60 mM	0.0385 mL	0.1927 mL	0.3854 mL	0.9636 mL
	80 mM	0.0289 mL	0.1445 mL	0.2891 mL	0.7227 mL
	100 mM	0.0231 mL	0.1156 mL	0.2313 mL	0.5781 mL